+1,831.5%
AEHR vs GSK
+105.0%
+1,726.6%
-87.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -6.7% | +0.5% | -7.2% | -6.7% |
| 7D | +6.4% | +1.1% | +5.2% | +6.1% |
| 30D | -20.3% | +6.3% | -26.6% | -21.5% |
| 3M | -53.8% | +1.8% | -55.6% | -54.3% |
| 6M | -44.8% | +1.7% | -46.5% | -45.8% |
| YTD | +182.2% | +6.5% | +175.7% | +173.0% |
| 1Y | +174.7% | +9.5% | +165.2% | +163.8% |
| 3Y | +143.5% | +65.3% | +78.2% | +103.8% |
| 5Y | +129.9% | +43.7% | +86.1% | +95.9% |
| All | +1,831.5% | +105.0% | +1,726.6% | +1,291.8% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling